Skip to main content
OpenTrials
Completed

NCT Number: NCT05420142

Determination of In-vivo Plasma AA Appearance From Plant Protein Fibre Products

This study aims to assess the digestibility and efficacy of the study groups previously developed innovative plant-based protein and fibre products.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University college Dublin, Dublin, Leinster, Ireland

Loading trial locations.

About this study

Older people are at high risk of undernutrition, which leads to serious adverse health outcomes, but effective preventive strategies are lacking. Effective, new strategies should focus on the etiology of undernutrition and directly address potential causes and mechanisms underpinning undernutrition.

Reduced food intake and restricted dietary diversity are direct consequences of poor appetite. Recent studies have shown, that older persons with a poor appetite demonstrate lower intake of protein and dietary fibre, and of several nutrient-rich food groups (e.g. meat, fish, wholegrains, vegetables), after adjustment for energy intake and other potential confounders, but a higher consumption of food groups low in micronutrients (e.g. fats, oils, sweets, and sodas), compared to those with good appetite.

Enhancing dietary protein and fibre intake in older Europeans is a key objective because intake of both nutrients is sub- optimal, not only in those with poor appetite. Adequate protein intake prevents excessive decline in muscle mass and function (sarcopenia), a widespread health-issue in older persons, intensified by undernutrition. Adequate dietary fibre intake prevents constipation and impedes the development of many chronic diseases prevalent in older people. Thus, targeting adequate protein and fibre intake may be particularly beneficial in this vulnerable population.

A preparatory short-term study will be performed to assess in 10 healthy older adults the net peripheral Amino Acid (AA) appearance following ingestion of 3 selected Plant-based Proteins and Fibre (PPF) products previously developed by the wider study collaborators, compared to the reference of 30 g whey protein. Plasma concentrations of AA from arterialised blood will be measured by ion exchange chromatography in blood samples (1 drawn before and 6 during 3 hours postprandial). This step will allow the research group to compare in-vitro (previous work) and in-vivo digestibility of several PPF mixtures and identify the product with both optimal amino acid composition and sensory properties as well as optimal post-prandial plasma amino acid profile to be used in further studies.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Community-dwelling, Age 65+ years, not a heavy smoker (≤10/day), BMI 18-30 kg/m2

Exclusion criteria

  • Medical condition or medication known to impact appetite or energy intake, consumes more than 14 (female) or 21 (male) units of alcohol per week, inability to come to study centre, self-reported cognitive impairment or diagnosis of clinical depression, heavy smoker (>10/day)

Treatment and study plan

Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey

Dietary Supplement

The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.

Primary outcomes

  1. Acute change in amino acid appearance in peripheral blood following a test meal ingestion

    Time frame: Blood samples will be taken at baseline, and at 30, 60, 90, 120, 150, & 180 minutes following ingestion of test sample

    Arterialised blood samples will be drawn from antecubital vein and centrifuged at 4˚C for 10 minutes at 4000rpm and frozen at -80˚C until analysed. Samples will be analysed using HPLC methods and expressed in μmol/L.

Secondary outcomes

  1. Acute changes in appetite and desire to eat

    Time frame: baseline, 30, 60, 90, 120, 150, & 180 minutes following ingestion of a sample meal

    Changes in appetite and are assessed at set time points throughout the testing session, matched for timing of biological sample collection. This will be assessed using the validated visual analogue scale (VAS) method. The Visual Analogue Scale is a 100mm scale with anchors on each end describing extreme answers. On the left side of the scale is the extreme negative response and the right side the positive response. Participants mark the line were appropriate between both extremes.

  2. Sensory properties and palatability of the test meal after ingestion

    Time frame: Immediately following test meal ingestion (single measure)

    Participants will rate each test meal on their perceived sensory properties and rate different aspects related to its palatability. These are important considerations when developing new products and will be assessed using the validated visual analogue scale (VAS) method. The Visual Analogue Scale is a 100mm scale with anchors on each end describing extreme answers. On the left side of the scale is the extreme negative response and the right side the positive response. Participants mark the line were appropriate between both extremes.

Sponsors and collaborators

Lead sponsor

University College Dublin

Other

Collaborators

  • Fraunhofer Institute for Interfacial Engineering and Biotechnology
  • Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
  • University of Padova

Registry information

Official study title

Innovative plAnt Protein Fibre and Physical Activity Solutions to Address Poor appEtite and prevenT undernutrITion in oldEr Adults (APPETITE): Determination of In-vivo Plasma AA Appearance From Plant Protein Fibre Products

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Jun 15, 2022
Registry last updated
Sep 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.